Therakos Overview
- Year Founded
-
1984
- Status
-
Private
- Employees
-
178
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
5
Therakos General Information
Description
Provider of extracorporeal photopheresis immune modulation therapy intended to help enhance immunologic response. The company specializes in the treatment of skin symptoms of mycosis and the treatment decisions can incorporate the disease stage, overall prognosis, patient quality of life, and most bothersome symptoms, thereby helping patients to cure themselves.
Contact Information
Website
www.therakos.comCorporate Office
- 3 Lotus Park
- The Causeway
- Staines-upon-Thames TW18 3AG
- England, United Kingdom
Corporate Office
- 3 Lotus Park
- The Causeway
- Staines-upon-Thames TW18 3AG
- England, United Kingdom
Therakos Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Therakos Comparisons
Industry
Financing
Details
Therakos Competitors (8)
One of Therakos’s 8 competitors is Igenomix USA, a Formerly PE-Backed company based in Paterna, Spain.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Igenomix USA | Formerly PE-Backed | Paterna, Spain | ||||
| Exact Sciences | Formerly VC-backed | Madison, WI | ||||
| Biocept | Formerly VC-backed | San Diego, CA | ||||
| Natera | Formerly VC-backed | Austin, TX | ||||
| Stemedica | Venture Capital-Backed | San Diego, CA |
Therakos Patents
Therakos Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10335452-B2 | Method of treating patients with hepatorenal syndrome type 1 | Active | 24-Oct-2014 | ||
| US-20160113994-A1 | Method of treating patients with hepatorenal syndrome type 1 | Active | 24-Oct-2014 | ||
| US-20200046798-A1 | Method of treating patients with hepatorenal syndrome type 1 | Inactive | 24-Oct-2014 | ||
| US-10758703-B2 | Systems and methods for providing a pulse of a therapeutic gas with a desired flow profile to maximize therapeutic effectiveness | Active | 17-Oct-2014 | ||
| US-20160106949-A1 | Systems and methods for providing a pulse of a therapeutic gas with a desired flow profile to maximize therapeutic effectiveness | Active | 17-Oct-2014 | A61M16/208 |
Therakos Signals
Therakos Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Therakos FAQs
-
When was Therakos founded?
Therakos was founded in 1984.
-
Where is Therakos headquartered?
Therakos is headquartered in Staines-upon-Thames, United Kingdom.
-
What is the size of Therakos?
Therakos has 178 total employees.
-
What industry is Therakos in?
Therakos’s primary industry is Drug Delivery.
-
Is Therakos a private or public company?
Therakos is a Private company.
-
What is the current valuation of Therakos?
The current valuation of Therakos is .
-
What is Therakos’s current revenue?
The current revenue for Therakos is .
-
How much funding has Therakos raised over time?
Therakos has raised $40.6M.
-
Who are Therakos’s investors?
CVC Capital Partners has invested in Therakos.
-
Who are Therakos’s competitors?
Igenomix USA, Exact Sciences, Biocept, Natera, and Stemedica are some of the 8 competitors of Therakos.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process